Application of gamma-delta T cells obtained by ascites filtration for immunotherapy against malignant refractory ascites-Reference-Cited by-同舟云学术

Application of gamma-delta T cells obtained by ascites filtration for immunotherapy against malignant refractory ascites

Published:2019-07-30 Issue:2 Volume:27 Page:73-79
ISSN:1344-6835
Container-title:Annals of Cancer Research and Therapy
language:en
Short-container-title:Ann. Cancer Res. Therap.

Author:

Abe Yuki¹,Kobayashi Hirohito²,Kanno Toshiyuki¹,Akizawa Yoshika¹,Ishitani Ken¹³,Hashimoto Kazunori⁴,Matsui Hideo⁵,Tabata Tsutomu¹

Affiliation:

1. Department of Obstetrics and Gynecology, Tokyo Women’s Medical University

2. Department of Transfusion and Cell Therapy, Tokyo Women’s Medical University Medical Center East

3. Department of Gynecology, Kitasato University Kitasato Institute Hospital

4. Department of Obstetrics and Gynecology, Tokyo Women’s Medical University Medical Center East

5. Department of Gynecology, Funabashi Futawa Hospital

Publisher

The Japanese Society of Strategies for Cancer Research and Therapy

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://www.jstage.jst.go.jp/article/acrt/27/2/27_73/_pdf

Reference18 articles.

1. 1) Matsusaki, K., Ohta, K., Yoshizawa, A., Gyoda, Y. and Japanese CART Study Group. (2011) Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int. J. Clin. Oncol. 16: 395–400. DOI: 10.1007/s10147-011-0199-1

2. 2) Ueda, T., Maehara, M., Takahashi, Y., Nakayama, N., Kondo, H., Shirota, K., Yoshizato, T. and Miyamoto, S. (2012) Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res. 32: 2353–2357.

3. 3) Togami, S., Hori, S., Kamio, M., Matsuo, T., Yoshinaga, M. and Douchi, T. (2014) Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis. Eur. J. Gynaecol. Oncol. 35: 301–303.

4. 4) Heiss, M.M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O.O., Ivanchenko, V.V., et al. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int. J. Cancer 127: 2209–2221. DOI: 10.1002/ijc.25423

5. 5) Eskander, R.N., Tewari, K.S. (2013) Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin. Pharmacol.5(Suppl 1): 55–61. DOI: 10.2147/CPAA.S45885

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reappraisal of a renovated cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites;2023-09-12